Pharmacytimes: Condition Center: Cardiovascular Health http://www.pharmacytimes.com/condition-resources/cardiovascular-health/condition-rss Cardiovascular Health en-us Sat, 21 Oct 2017 11:01:24 UTC Sat, 21 Oct 2017 11:01:24 UTC Statins Provide Heart Benefits Beyond Cholesterol Lowering http://www.pharmacytimes.com/resource-centers/cardiovascular-health/statins-provide-heart-benefits-beyond-cholesterol-lowering The benefits of statins may be more far-reaching than previously thought, according to research presented at EuroCMR 2017 last week.  9:11 AM, Thu June 1, 2017 AHA: Patients Uncertain About Cholesterol Management http://www.pharmacytimes.com/resource-centers/cardiovascular-health/aha-patients-uncertain-about-cholesterol-management A new survey conducted by the American Heart Association (AHA) has found that patients are often uncertain about how to manage their cholesterol, according to a press release about the AHA’s findings.  7:00 AM, Thu April 13, 2017 Study: Coronary Artery Calcium Score Identifies Statin-Eligible African Americans http://www.pharmacytimes.com/resource-centers/cardiovascular-health/study-coronary-artery-calcium-score-identifies-statineligible-african-americans A recent study has examined the accuracy of the US Preventive Services Task Force (USPSTF) and American College of Cardiology/American Heart Association (ACC/AHA) recommendations for identifying African American individuals who would benefit from statins.  9:11 AM, Mon March 27, 2017 Could Pharmacogenetic Dosing Reduce Warfarin-Related Adverse Events? http://www.pharmacytimes.com/resource-centers/cardiovascular-health/could-pharmacogenetic-dosing-reduce-warfarinrelated-adverse-events Personalizing doses of warfarin through genetic testing helped reduce the risk of combined adverse events in patients undergoing elective orthopedic surgery, according to data presented at the American College of Cardiology's 66th Annual Scientific Session.  1:19 PM, Mon March 20, 2017 Omega-3 Fish Oil: Insufficient Evidence of Heart Disease Prevention http://www.pharmacytimes.com/resource-centers/cardiovascular-health/omega3-fish-oil-insufficient-evidence-of-heart-disease-prevention The American Heart Association (AHA) has published a new science advisory stating that there is not enough evidence to support the use of fish oil supplementation as a primary prevention of cardiovascular disease in the general population.  8:00 AM, Mon March 20, 2017 Younger Women Less Likely to Receive Preventive Care for Heart Disease http://www.pharmacytimes.com/resource-centers/cardiovascular-health/younger-women-less-likely-to-receive-preventive-care-for-heart-disease Younger women are less likely to be screened for cardiovascular disease (CVD) and treated with preventive medicine than men, a recent study found.  2:52 PM, Mon March 6, 2017 Drug Shortages: Manufacturer Accountability Increasing http://www.pharmacytimes.com/resource-centers/cardiovascular-health/drug-shortages-manufacturer-accountability-increasing All over the world, drug shortages cause complex and risky adjustments to medical regimens.  8:00 AM, Thu February 23, 2017 Sodium-Glucose Cotransporter 2 Inhibitors: Possible Role in Cardiology http://www.pharmacytimes.com/resource-centers/diabetes/sodiumglucose-cotransporter-2-inhibitors-possible-role-in-cardiology- Sodium-glucose cotransporter 2 (SGLT2) inhibitors are an emerging antidiabetic class that offer significant cardiovascular risk reduction. 10:14 AM, Tue January 10, 2017 Pediatric Cardiovascular Conditions http://www.pharmacytimes.com/publications/issue/2016/December2016/pediatric-cardiovascular-conditions Cardiovascular health in pediatric patients remains a topic that requires continual education. 11:19 AM, Mon December 12, 2016 Nutritional Supplements for Promoting Cardiovascular Health http://www.pharmacytimes.com/publications/issue/2016/December2016/nutritional-supplements-for-promoting-cardiovascular-health According to the World Health Organization, cardiovascular disease is the leading global cause of death among men and women, accounting for an estimated 17.5 million deaths worldwide each year. 8:55 AM, Sat December 3, 2016 Aspirin, Omeprazole Combination Treatment Yosprala Approved http://www.pharmacytimes.com/product-news/aspirin-omeprazole-combination-treatment-yosprala-approved The FDA recently approved Aralez Pharmaceuticals' Yosprala, a once-daily, fixed-dose combination of the antiplatelet agent aspirin and the proton pump inhibitor omeprazole. 7:00 AM, Mon September 26, 2016 3 Common Barriers to Cardiac Medication Adherence http://www.pharmacytimes.com/news/3-common-barriers-to-cardiac-medication-adherence Pharmacists can help evaluate and address adherence barriers among patients taking medications for cardiovascular disease. 8:54 AM, Wed May 18, 2016 Cardiovascular Medication Adherence Not Commonly Discussed with Physicians http://www.pharmacytimes.com/contributor/douglas-jennings-pharmd-fccp-faha/2016/05/cardiovascular-medication-adherence-not-commonly-discussed-with-physicians Despite advances in preventative drug therapy, cardiovascular disease remains the leading cause of death in the United States. 4:45 AM, Wed May 18, 2016 Vitamin C Linked to Lower Cardiovascular Disease Risk http://www.pharmacytimes.com/publications/issue/2016/April2016/Vitamin-C-Linked-to-Lower-Cardiovascular-Disease-Risk Maintaining a diet with a high level of vitamin C could reduce a patient's risk of cardiovascular disease and early death. 9:29 PM, Sun April 17, 2016 Entresto Shows Benefit Even in Clinically Stable Heart Failure Patients http://www.pharmacytimes.com/resource-centers/heart-failure/entresto-shows-benefit-even-in-clinically-stable-heart-failure-patients Novartis' sacubitril/valsartan (Entresto) is showing promise for heart failure patients with reduced ejection fraction, regardless of background therapy or clinical stability. 7:00 AM, Thu April 14, 2016 Early Follow-Up Care After Heart Attack Key to Medication Adherence http://www.pharmacytimes.com/news/early-follow-up-care-after-heart-attack-key-to-medication-adherence Patients receiving follow-up care more than 6 weeks after a heart attack are much less likely to stick to their medication regimen. 10:30 PM, Wed March 23, 2016 FDA Rejects New Indication for Zetia and Vytorin http://www.pharmacytimes.com/product-news/fda-rejects-new-indication-for-zetia-and-vytorin Merck has received a complete response letter from the FDA regarding its supplemental new drug applications for ezetimibe and ezetimibe and simvastatin. 7:00 AM, Thu February 18, 2016 Supplements for Cardiovascular Health: Navigating Crowded Shelves http://www.pharmacytimes.com/publications/issue/2015/December2015/Supplements-for-Cardiovascular-Health-Navigating-Crowded-Shelves Cardiovascular disease is the leading global cause of death among men and women, annually accounting for an estimated 17.3 million deaths worldwide. 2:58 AM, Tue December 15, 2015 ACS Patient Nonadherence Factors Pharmacists Should Target http://www.pharmacytimes.com/resource-centers/ACS/acs-patient-nonadherence-factors-pharmacists-should-target Seven in 10 patients report some extent of nonadherence prior to a hospitalization caused by a cardiovascular event such as acute cardiac failure. 12:00 AM, Fri November 6, 2015 Parkinson's Drug Does Not Increase Risk of Cardiovascular Events http://www.pharmacytimes.com/product-news/parkinsons-drug-does-not-increase-risk-of-cardiovascular-events The FDA has determined that entacapone, a drug used in the treatment of Parkinson's disease, does not increase patients' risk of heart attacks, stroke, or other cardiovascular events. 9:03 PM, Tue October 27, 2015